Heart monitoring for cancer patients receiving chemotherapy and targeted drugs
Official title: Development of an Active Surveillance System for Adverse Reactions to Molecular Targeted Drugs Based on Biomarkers and Personalized Medicine and Its Impact on Patient Quality of Life
Run by Sixth Affiliated Hospital, Sun Yat-sen University · NCT07058454 · Data updated 2026-11-12
This project will test whether regular heart checks (blood biomarkers, ECG, and echocardiogram) can predict serious heart problems in adults getting chemotherapy or targeted cancer drugs.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, trastuzumab, bevacizumab |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | September 1, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | December 29, 2025 |
| Trial ID | NCT07058454 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with a pathologically confirmed cancer who are receiving or planning to receive chemotherapy or targeted cancer therapies and are willing to provide informed consent and biological samples.
✕Probably not a fit
Patients with recent severe cardiovascular or cerebrovascular events, incomplete medical records, or who cannot complete planned chemotherapy or follow-up at the study center are unlikely to benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational effort to monitor cardiac outcomes in adults undergoing chemotherapy or molecularly targeted cancer therapies. Participants will undergo periodic cardiac evaluations including ECG, echocardiography, and biomarker testing (troponin T, NT‑proBNP), with blood samples collected for genomic analysis. Local factors (for example, central venous catheter–related thrombosis) and systemic factors (age, comorbidities, BMI, genetic variants) will be integrated to develop a predictive model for major adverse cardiovascular events (MACE). The study will also track the impact of cardiotoxicity and the monitoring strategy on patients' quality of life.
Why it matters
Potential benefit: If successful, the model could help detect heart damage earlier and guide personalized monitoring or treatment to reduce major cardiac events.
How similar studies have gone: Previous research has shown biomarkers like troponin and NT‑proBNP can detect early cardiotoxicity, but combining imaging, clinical and local catheter-related factors with genomics into a validated predictive model is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1.Adults (age \> 18 years) with a pathologically confirmed malignant tumor (any type of cancer); 2.Currently receiving or planning to receive chemotherapy (including regimens containing molecular targeted drugs) as adjuvant treatment for cancer; 3.Willing and able to participate in the study with provision of informed consent, and agreeable to provide required clinical data and biological samples. \- Exclusion Criteria: 1. Incomplete basic patient information or medical records (missing key data necessary for the study); 2. Failure to complete the full course of planned chemotherapy at the study center (e.g., patient did not adhere to or finish all cycles of adjuvant chemotherapy at our institution); 3. History of severe acute cardiovascular or cerebrovascular events within 6 months prior to enrollment, including acute heart failure, acute myocardial infarction, acute intracerebral hemorrhage (stroke), malignant arrhythmia, or New York Heart Association (NYHA) Class IV/V heart failure; 4. Missing essential pre- or post-chemotherapy evaluations: patients who did not undergo complete baseline or end-of-treatment assessments (such as blood routine, hepatic/renal function, coagulation profile, cardiac enzymes (troponin T), NT-proBNP (or BNP), 12-lead ECG, and echocardiogram)
Where it's running
-
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Principal investigator: xiaoyan li — Sixth Affiliated Hospital, Sun Yat-sen University
- Study coordinator: xiaoyan li
- Email: lixyan5@mail.sysu.edu.cn
- Phone: 13609066172
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.